@entity3216 and XXXX decrease @entity392 modulating the auditolimbic dopaminergic pathway.

@entity1 @entity935 @entity3216 @entity1132 @entity2493 @entity392
OBJECTIVES: @entity3216 and @entity2493 decrease @entity935 activity. @entity3216 , a D2 antagonist of @entity935 receptors, and @entity2493 , a pineal substance with antidopaminergic action, are administered to @entity392 @entity1 to decrease @entity392 . DESIGN: A prospective, randomized, double-blinded, placebo-controlled study was done. SETTING: General otorhinolaryngologic consultation for 2002-2004 in Seville, Spain. METHODS: One hundred twenty @entity1 consulted for subjective @entity392 . They were included randomly in four groups of 30. One group took @entity3216 (50 mg/8 h) alone, the second group took @entity2493 (3 mg/24 h), the third group took the same doses of @entity3216 (50 mg/8 h) plus @entity2493 (3 mg/24 h), and the fourth group took placebo ( @entity1132 50 mg/8 h), all for 1 month. Ninety-nine @entity1 completed the study. MAIN OUTCOME MEASURES: Clinical history, tonal audiometry, tympanometry, and tinnitometry were done at the beginning and end of the study. Subjective grading of @entity392 and a visual analogue scale (0-10) were done for evaluation of results. RESULTS: Based on the subjective grading, @entity392 diminished by 56% in @entity1 treated with @entity3216 , by 40% in @entity1 treated with @entity2493 , by 81% in @entity1 treated with @entity3216 plus @entity2493 , and by 22% in @entity1 treated with placebo. Based on the visual analogue scale, @entity392 diminished from 7.7 to 6.3 in @entity1 treated with @entity3216 , to 6.5 in those treated with @entity2493 , to 4.8 in @entity1 treated with @entity3216 plus @entity2493 , and to 7.0 in those treated with placebo. CONCLUSIONS: @entity3216 and @entity2493 reduce @entity392 , decreasing @entity935 activity. The @entity392 auditolimbic dopaminergic pathway has broad therapeutic implications.
